PharmiWeb.com - Global Pharma News & Resources

Medical comms - Press Releases

Date Title Company
08-Dec-2020 RetinAI Announces Collaboration with Novartis to Provide Artificial Intelligence Solutions in Ophthalmology RetinAI Medical AG
08-Dec-2020 Pioneering COVID-19 Test Detects Virus with Smartphone Two-Photon Research Inc
08-Dec-2020 RNA Therapeutics Conference brings together industry experts and holistic view on the latest developments SMi Group Ltd
08-Dec-2020 Exclusive interview with Dr Eric Noehrenberg, President, NIPC released ahead of Parallel Trade conference 2021 SMi Group Ltd
07-Dec-2020 YESCARTA® (AXICABTAGENE CILOLEUCEL) IS FIRST CAR T CELL THERAPY TO DEMONSTRATE HIGH RESPONSE RATES AND DURABLE CLINICAL BENEFIT IN A PIVOTAL INDOLENT NON-HODGKIN LYMPHOMA STUDY Kite, a Gilead Company
07-Dec-2020 Nokia and Vi CSR deploy SmartAgri solution to enhance farming practices of 50,000 farmers Nokia and Vodafone India Foundation
07-Dec-2020 Medigene AG: Detailed analysis from Medigene's completed Phase I/II DC vaccine in AML patients presented orally at ASH 2020 Medigene
07-Dec-2020 Transgene appoints Hedi Ben Brahim as Chairman and Chief Executive Officer Transgene
07-Dec-2020 Stress and anxiety levels increasing in NHS staff during COVID-19 Nuance
07-Dec-2020 Moberg Pharma publishes prospectus relating to the rights issue Moberg Pharma AB
07-Dec-2020 Kaia Health and Chiesi Group Announce Strategic Partnership to Commercialise Kaia COPD Pulmonary Rehabilitation App in European Markets Kaia Health
07-Dec-2020 Biophytis –Upcoming Potential Value Generating Milestones Biophytis SA
07-Dec-2020 Exclusive interview with Séverine Duband, Nemera released ahead of Pre-filled Syringes Europe SMi Group Ltd
06-Dec-2020 MAGROLIMAB DEMONSTRATES CLINICAL RESPONSES IN ONGOING PHASE 1B TRIAL OF PREVIOUSLY UNTREATED ACUTE MYELOID LEUKAEMIA PATIENTS Gilead Sciences, Inc.
06-Dec-2020 NEW FOUR-YEAR DATA SHOW LONG-TERM SURVIVAL IN PATIENTS WITH RELAPSED/REFRACTORY LARGE B CELL LYMPHOMA TREATED WITH YESCARTA® (AXICABTAGENE CILOLEUCEL) IN ZUMA-1 TRIAL Kite, A Gilead Company
06-Dec-2020 YESCARTA® (AXICABTAGENE CILOLEUCEL) IS FIRST CAR T CELL THERAPY TO DEMONSTRATE HIGH RESPONSE RATES AND DURABLE CLINICAL BENEFIT IN A PIVOTAL INDOLENT NON-HODGKIN LYMPHOMA STUDY Kite, A Gilead Company
04-Dec-2020 PharmiWeb.Jobs Welcomes Experis PharmiWeb.Jobs
04-Dec-2020 Olympus Grows Respiratory Portfolio with Acquisition of Veran Medical Technologies, Inc. Olympus
02-Dec-2020 UK biotech company ILC Therapeutics announces first international investment ILC Therapeutics
02-Dec-2020 Kallik becomes first artwork and labelling management software company to offer customers the security of Amazon Web Services Kallik